Medications taken before or during pregnancy.

<p>Data are shown as <i>n</i> (%), with percentages referring to complete data only.</p

Case reporting and completeness of data collection.

<p>Case reporting and completeness of data collection.</p

Birth outcomes for 77 fetuses born to liver and cardiothoracic transplant recipients¹.

<p>¹Data have been grouped for confidentiality purposes, due to small numbers.</p><p>²Includes 57 livebirths to women with liver transplants and 13 livebirths to women with cardiothoracic transplants.</p

Maternal outcomes in liver and cardiothoracic transplant recipients.

<p>Data are shown as <i>n</i> (%), with percentages referring to complete data only.</p>1<p>Grade 1 involves an immediate threat to the life of the woman or fetus; Grade 2 involves maternal or fetal compromise which is not immediately life-threatening; Grade 3 involves a need for early delivery but no maternal or fetal compromise; Grade 4 requires delivery at a time to suit the woman and maternity team <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0089151#pone.0089151-Royal1" target="_blank">[36]</a>.</p

Indication for transplantation in liver transplant recipients (n = 56) and cardiothoracic transplant recipients (n = 14).

<p>Indication for transplantation in liver transplant recipients (n = 56) and cardiothoracic transplant recipients (n = 14).</p

Highest serum creatinine level during each trimester of pregnancy, for liver and cardiothoracic transplant recipients.

<p>Highest serum creatinine level during each trimester of pregnancy, for liver and cardiothoracic transplant recipients.</p

Demographic, maternal and transplant characteristics of liver and cardiothoracic transplant recipients.

<p>Data are shown as <i>n</i> (%), with percentages referring to complete data only.</p>1<p>Reported for 70 transplant women, rather than 76 pregnancies, as this characteristic will not have changed with repeated pregnancies.</p

Principal maternal outcomes by level of proteinuria adjusted for age and ethnicity with risk ratios in comparison with PE 300 group (proteinuria 300- 499 mg/24 hours).

<p>Data are given as mean (standard deviation) or number (percentage) together with risk ratios and 95% confidence intervals (CI).</p><p>Risk ratio, p in comparison with preeclampsia with proteinuria of 300 - 499 mg/24 hours; *P≤0.05; **P≤0.01; ***P≤0.001 </p

Demographics, risk factors and medications at enrolment to study.

<p>Data are given as mean (standard deviation) or number (percentage). Abbreviations: ONS: Office for National Statistics; BMI: Body Mass Index; </p><p>* PE300 and PE500 compared with both CH or GH groups P<0.0001; ** CHT compared with PE300, PE500 and GH P<0.0001</p

Principal perinatal outcomes by level of proteinuria adjusted for age and ethnicity with risk ratios in comparison with PE 300 group (proteinuria 300- 499 mg/24 hours).

<p>Risk ratio: comparison with preeclampsia with proteinuria of 300–499 mg/24 hours; *P≤0.05; **P≤0.01; ***P≤0.001 </p